An improved formulation of Scandinavian Bioharmas ETEC vaccine candidate is currently being tested in an immunogenicity bridging study

An improved user-friendly formulation of the world’s most advanced ETEC vaccine candidate, ETVAX®, has been developed to meet commercial requirements. We want to ensure that the new formulation gives rise to immune responses that are not inferior to the previous formulation of the vaccine that underwent earlier testing. This is done in a phase II double-blinded, […]